icon-folder.gif   Conference Reports for NATAP  
 
  The International Liver Congress™
EASL - European Association for the
Study of the Liver
June 22-26 2022
Back grey_arrow_rt.gif
 
 
 
Biomarkers, Imaging, & Safety in a Well-compensated NASH Cirrhotic Cohort Treated With Resmetirom, a Thyroid Hormone Receptor Beta Agonist, for 52 Weeks
 
 
  EASL 2022 June 22-26 London
 
Stephen A. Harrison,1 Kris V. Kowdley,2 Rebecca A. Taub,3 Naim Alkhouri,4 Guy W. Neff5 1University of Oxford, United Kingdom & Pinnacle Clinical Research, San Antonio, TX, USA; 2Liver Institute Northwest, Seattle, WA, USA;
3Madrigal Pharmaceuticals, Conshohocken, PA, USA; 4Arizona Liver Health, Tucson, AZ, USA; 5Covenant Metabolic Specialists,
Sarasota, FL, USA

0705221

0705222

0705223

0705224

0705225

0705226

0705227